Cost-effectiveness of pemetrexed in combination with cisplatin as first line treatment for patients with advanced non-squamous non-small-cell

Cost-effectiveness of pemetrexed in combination with cisplatin as first line treatment for patients with advanced non-squamous non-small-cell

Introduction: Lung cancer is the third most frequent neoplastic tumour in Spain, with around 27 000 new cases diagnosed per year; 80-95% of these are non-small-cell cancer (NSCLC), and the majority of cases are diagnosed in advanced stages of the disease, and for this reason it is one of the onco...

Full description

Saved in:
Bibliographic Details
Main Authors: Jonathan González García, Fernando Gutiérrez Nicolás, Gloria Julia Nazco Casariego, Cristina Valcárcel Nazco, Jose Norberto Batista López, Juana Oramas Rodríguez
Format: Article
Language:English
Published: Elsevier 2017-01-01
Series:Farmacia Hospitalaria
Subjects:
Non-small-cell lung cancer
Cost-effectiveness
; Economic evaluation
; Cisplatin
; Pemetrexed
Bevacizumab
Online Access:http://www.aulamedica.es/fh/pdf/10142.pdf
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.aulamedica.es/fh/pdf/10142.pdf

Similar Items